Raj Gandesha

Partner, New York

Biography

Major companies look to Raj Gandesha for his counsel on complex intellectual property, antitrust and commercial litigations.

Overview

Raj represents clients in complex intellectual property, antitrust and commercial litigations. He has worked on high-profile, 'bet the company' cases that have helped shape IP and antitrust law.

Raj also advises clients with respect to personal data privacy matters, including cross-border transfers of personal data, security breach notification issues and Internet privacy policies.

His client list is varied and international in scope and includes companies operating in the pharmaceutical, oil, IT, consumer health, entertainment and financial services industries. He regularly represents both national and multinational businesses with cross-border interests.

Bars and Courts
New York State Bar
US District Court for the Southern District of New York
US District Court for the Eastern District of New York
Education
JD
University of Toronto Faculty of Law
BA
(First Class Hons.), Politics, Philosophy and Economics
Oxford University
Languages
English

Experience

Pfizer, 2014–ongoing
Raj is representing Pfizer in federal class action antitrust litigations with respect to Celebrex, accusing the company of delaying entry of generic competition for Celebrex through alleged fraud on the US patent office and sham patent litigation. In re Celebrex Antitrust Litigation (E.D. Va.).

Pfizer, 2011–ongoing
Raj is representing Pfizer in federal consolidated class action antitrust litigations and a state court action brought by the West Virginia Attorney General with respect to Lipitor, which accused the company of delaying entry of generic competition for Lipitor through alleged fraud on the US patent office and sham patent litigation, a sham FDA citizen petition and a reverse payment settlement agreement. In re Lipitor Antitrust Litigation (D.N.J.); State of West Virginia v. Pfizer, Inc., et al. (Cir. Ct., Mason Cty., W.V.).

Pfizer, 2011–ongoing
Raj is representing Pfizer in federal class action antitrust litigations with respect to Effexor XR, accusing the company of delaying entry of generic competition for Effexor XR through alleged fraud on the US patent office, sham patent litigation and a reverse payment settlement agreement. In re Effexor XR Antitrust Litigation (D.N.J.).

Sandoz, 2009–present
Raj has represented Sandoz in multiple state and federal actions alleging false claims act, common law fraud and consumer protection claims based on allegations that drug manufacturers reported inaccurate pricing benchmarks that allegedly caused state Medicaid agencies to overpay for prescription drugs provided to Medicaid beneficiaries.